NCT05638594View on ClinicalTrials.gov

Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

236

Participants

Timeline

Start Date

December 20, 2022

Primary Completion Date

December 10, 2025

Study Completion Date

December 10, 2027

Conditions
Breast Cancer
Interventions
DRUG

Pyrotinib

320mg, qd

DRUG

Trastuzumab

8 mg/kg first dose, then 6 mg/kg，q3w

DRUG

Dalpiciclib

125mg , qd，d1-21, q4w

DRUG

Letrozole

2.5mg，qd

DRUG

Pertuzumab

840 mg first dose, then 420 mg, q3w

DRUG

Docetaxel

75 mg/m2, q3w

DRUG

Carboplatin

AUC 6, q3w

DRUG

Gonadotropin-releasing hormone agonist

Every 4 weeks for 5 cycles, premenopausal patients only

Trial Locations (1)

110004

RECRUITING

Shengjing Hospital of China Medical University, Shenyang

All Listed Sponsors
lead

Shengjing Hospital

OTHER